Abstract 5710
Background
Merkel cell carcinoma (MCC) is a rare, aggressive tumour of the skin associated with high recurrence rates and poor survival. Clinical trials have shown activity of various checkpoint inhibitors targeting programmed death-(ligand)-1 (PD-(L)1). Avelumab is currently the only PD-L1 inhibitor that has been approved in the Netherlands for advanced/metastatic MCC (mMCC). Here, we report the Dutch real-world efficacy data of avelumab in patients with mMCC.
Methods
All mMCC patients from 4 tertiary referral centres in the Netherlands from December 2016 were analysed. Patients were included in this analysis if they had received avelumab for mMCC, regardless of other previous lines of therapy. Patient data were collected retrospectively and followed up prospectively after initiation of data collection. Primary endpoints were response rate (RR) and duration of response (DOR) , secondary endpoints were progression free survival (PFS), overall survival (OS) and toxicity. Toxicity was evaluated according to CTCAE version 5.0.
Results
Forty-six patients received avelumab, of which 37 patients were evaluable for response (9 had not reached response evaluation, 1 died due to comorbidity). In 22 (59.5%) patients avelumab was first-line treatment. Median follow up time was 7.8 (IQR 3.7-10.1) months. RR was 59.5% (n = 22) with 21.6% (n = 8) of patients having a complete radiological response. Median DOR was 6.3 (IQR 3.0-12.5) months and 15 (40.5%) patients had ongoing response at time of data analysis. Median PFS was 12.2 (95% CI 3.3-21.1) months, median OS was not yet reached. In subgroup analysis no differences were found for the presence of visceral metastases at baseline or previous lines of therapy. Five (13.2%) patients experienced grade 3 toxicity, of which 2 (4.3%) patients discontinued avelumab. No grade 4-5 toxicity were seen.
Conclusions
In the Netherlands treatment with avelumab is increasingly used in first- and second-line treatment for mMCC. In this real-world cohort, RR, DOR, PFS and toxicity results were in line with results from clinical trials and show relatively high, durable responses in patients with mMCC, unaffected by the presence of visceral metastases or previous lines of therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3140 - Phase 2 study of olaparib in previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) or homologous recombination repair deficiency (HRD): LYNK-002
Presenter: David Hyman
Session: Poster Display session 3
Resources:
Abstract
2655 - The K-BASKET trial: A prospective phase II biomarker-driven multiple basket trial in Korean solid cancer patients.
Presenter: Seul Kim
Session: Poster Display session 3
Resources:
Abstract
5938 - Cambridge Liquid biopsy “CALIBRATION” study: Can changes in circulating tumour DNA (ctDNA) predict durable tumour responses in patients with advanced oesophageal cancer receiving MEDI4736?
Presenter: Constanza Linossi
Session: Poster Display session 3
Resources:
Abstract
3799 - Validation of a tumour mutational burden workflow on routine histological samples of colorectal cancer and assessment of a cohort with synchronous hepatic metastases
Presenter: Andrea Mafficini
Session: Poster Display session 3
Resources:
Abstract
4647 - Microsatellite Instability Testing and Lynch Syndrome Screening For Colorectal Cancer Patients Through Tumor Sequencing
Presenter: Li Liu
Session: Poster Display session 3
Resources:
Abstract
3231 - "Liquid Withdarw" technique in CT-guided cutting needle lung biopsy: decreased incidence of complications and increased tissue amount for lung cancer molecular testing.
Presenter: Xue Wang
Session: Poster Display session 3
Resources:
Abstract
3282 - WGS Implementation in standard cancer Diagnostics for Every cancer patient (WIDE)
Presenter: Paul Roepman
Session: Poster Display session 3
Resources:
Abstract
5905 - Known and unknown gene fusion detection capabilities of solid tumor laboratories conducting next generation sequencing in 6 countries
Presenter: Steph Finucane
Session: Poster Display session 3
Resources:
Abstract
4238 - Clinical and Analytical Accuracy of a 523 Gene Panel Next-Generation Sequencing (NGS) Assay on Formalin-Fixed Paraffin-Embedded (FFPE) Solid Tumor Samples
Presenter: Ina Deras
Session: Poster Display session 3
Resources:
Abstract
2493 - Methylation analysis of MLH1 using droplet digital PCR and methylation sensitive restriction enzyme.
Presenter: Celine De Rop
Session: Poster Display session 3
Resources:
Abstract